Latest data from Novartis SPRINT trial of Zolgensma confirms the benefits of pre-symptomatic treatment

Latest data from the SPR1NT trial has been released, again confirming the impact of Zolgensma for children at risk for SMA who are treated before the onset of symptoms. In sharp contrast to the natural course of SMA, children treated pre-emptively with Zolgensma are standing and walking, with few or no signs of neuromuscular disease.